Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists

Neuroendocrinology

Volumn 89, Issue 2, 2009, Pages 163-170

  Passos, Vanessa Q ^a,b   Fortes, Maria Angela H Z ^a   Giannella Neto, Daniel ^a   Bronstein, Marcello D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (United States)

Author keywords

Dopamine agonist; Estrogen receptor; Gene expression; Pituitary tumor transforming gene; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NERVE GROWTH FACTOR BETA SUBUNIT; NERVE GROWTH FACTOR RECEPTOR; PROLACTIN; SECURIN;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR SENSITIVITY; TISSUE SECTION; TREATMENT RESPONSE;

ADULT; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MALE; PITUITARY NEOPLASMS; PROLACTINOMA; RNA, MESSENGER;

EID: 61749102756     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156116     Document Type: Article

References (39)

1. Burrow G, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K: Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981;304:156-158.
2. Ben-Jonathan N, Hnasko R: Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-763.
3. Vance ML, Thorner MO: Prolactinomas. Endocrinol Metab Clin North Am 1987;16:731-753.
4. Molitch ME: Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002;5:55-65.
5. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Muratori M, Musatti L, Verbessem G, Scanlon MF: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409-413.
6. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, et al: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574-3579.
7. Musolino NR, Cunha-Neto B, Bronstein MD: Cabergolina como alternativa ao tratamento clinico de prolactinomas. Experiência na intolerância/ resistência à bromocriptina. Arq Bras Endocrinol Metabol 2000;44:139-143.
8. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904-909.
9. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.
10. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-509.
11. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM: Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumor size in bromocriptine-resistant prolactinomas. Clin Endocrinol (Oxf) 1991;34:25-29.
12. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994:60:314-322.
13. Pellegrini I, Costa R, Grisoli F, Jaquet P: Abnormal dopamine sensitivity in some human prolactinomas. Horm Res 1989;31:19-23.
14. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 1992;26:489-494.
15. Vilar L, Burke CW: Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol (Oxf) 1994;41:821-826.
16. Molitch ME: Dopamine resistance of prolactinomas. Pituitary 2003;6:19-27.
17. Lindsay RM: Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview. Philos Trans R Soc Lond [B] 1996;351:365-373.
18. Ibanez CF: Structure-function relationships in the neurotrophin family. J Neurobiol 1994;25:1349-1361.
19. Lamberts SW, Verleun T, Hofland L, Oosterom R: Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 1986;63:1342-1347.
20. Heaney AP, Fernando M, Melmed S: Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 2002;109:277-283.
21. Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-422.
22. Wang Z, Melmed S: Pituitary tumor transforming gene (PTTG) transforming and transactivating activity. J Biol Chem 2000;275:7459-7461.
23. -ΔΔCt method. Methods 2001;25:402-408.
24. NGFR-mediated activation of nuclear factor-kappaB. Mol Endocrinol 2002;16:353-366.
25. Facchetti M, Uberti D, Memo M, Missale C: Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. Mol Endocrinol 2003;18:162-172.
26. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994;60:314-322.
27. Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF: Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J Cancer 1995;72:1397-1399.
28. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R, et al: Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993;90:7961-7965.
29. 2 dopamine sensitive adenylate cyclase in anterior pituitary cells and striatal neurons in primary culture. J Neurochem 1989;52:410-418.
30. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S: Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 1999;5:1317-1321.
31. Chaidarun SS, Swearingen B, Alexander JM: Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. J Clin Endocrinol Metab 1998;83:3308-3315.
32. Takahashi S: Intrapituitary regulatory system of proliferation of mammotrophs in the pituitary gland. Zoolog Sci 2004;21:601-611.
33. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 1986;10:1167-1177.
34. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-131.
35. Gustafsson JA: An update on estrogen receptors. Semin Perinatol 2000;24:66-69.
36. Melmed S: Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-1618.
37. Horwitz GA, Miklovsky I, Heaney AP, Ren SG, Melmed S: Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol Endocrinol 2003;17:600-609.
38. Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene. Mol Endocrinol 1997;11:433-441.
39. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761-767.